Cargando…

Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis

BACKGROUND: To eliminate cervical cancer as a public health problem, the World Health Organization had recommended routine vaccination of adolescent girls with two doses of the human papillomavirus (HPV) vaccine before sexual initiation. However, many countries have yet to implement HPV vaccination...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prem, Kiesha, Choi, Yoon Hong, Bénard, Élodie, Burger, Emily A., Hadley, Liza, Laprise, Jean-François, Regan, Mary Caroline, Drolet, Mélanie, Sy, Stephen, Abbas, Kaja, Portnoy, Allison, Kim, Jane J., Brisson, Marc, Jit, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463590/ https://www.ncbi.nlm.nih.gov/pubmed/37635227 http://dx.doi.org/10.1186/s12916-023-02988-3

Ejemplares similares

Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis
por: Bénard, Élodie, et al.
Publicado: (2022)

Now or later: Health impacts of delaying single‐dose HPV vaccine implementation in a high‐burden setting
por: Burger, Emily A., et al.
Publicado: (2022)

From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness
por: Jit, Mark, et al.
Publicado: (2021)

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model
por: Jit, Mark, et al.
Publicado: (2015)

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis
por: Bénard, Élodie, et al.
Publicado: (2023)

Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis
por: Drolet, Mélanie, et al.
Publicado: (2021)

Projections of human papillomavirus (HPV) vaccination impact in Ethiopia, India, Nigeria and Pakistan: a comparative modelling study
por: Portnoy, Allison, et al.
Publicado: (2021)

Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study
por: Abbas, Kaja M, et al.
Publicado: (2020)

Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries
por: Brisson, Marc, et al.
Publicado: (2020)

The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study
por: Portnoy, Allison, et al.
Publicado: (2020)

Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries
por: Canfell, Karen, et al.
Publicado: (2020)

Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review
por: Gingras, Guillaume, et al.
Publicado: (2016)

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country
por: Burger, Emily A., et al.
Publicado: (2018)

Projecting social contact matrices in 152 countries using contact surveys and demographic data
por: Prem, Kiesha, et al.
Publicado: (2017)

Immunogenicity of a Two-Dose Human Papillomavirus Vaccine Schedule in HIV-Infected Adolescents with Immune Reconstitution
por: Rungmaitree, Supattra, et al.
Publicado: (2022)

Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?
por: Drolet, Mélanie, et al.
Publicado: (2013)

Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries
por: Fu, Han, et al.
Publicado: (2021)

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries
por: Ochalek, Jessica, et al.
Publicado: (2020)

Potential lives saved in 73 countries by adopting multi‐cohort vaccination of 9–14‐year‐old girls against human papillomavirus
por: Jit, Mark, et al.
Publicado: (2018)

Building an adaptive dose simulation framework to aid dose and schedule selection
por: Hooijmaijers, Richard, et al.
Publicado: (2023)

Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males
por: Bergman, Hanna, et al.
Publicado: (2019)

Differential health impact of intervention programs for time-varying disease risk: a measles vaccination modeling study
por: Portnoy, Allison, et al.
Publicado: (2022)

Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis
por: Liu, Yang, et al.
Publicado: (2022)

VIII. Immunological Effectiveness of the Two Dose Schedule
por: Miller, David G., et al.
Publicado: (1962)

nab-Paclitaxel dose and schedule in breast cancer
por: Martín, Miguel
Publicado: (2015)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada
por: Skowronski, Danuta M, et al.
Publicado: (2022)

Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination
por: Lazcano-Ponce, Eduardo, et al.
Publicado: (2019)

Vaccine programme stakeholder perspectives on a hypothetical single-dose human papillomavirus (HPV) vaccine schedule in low and middle-income countries
por: Gallagher, Katherine E., et al.
Publicado: (2018)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis
por: Kim, Jane J., et al.
Publicado: (2021)

Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
por: Germar, Maria Julieta, et al.
Publicado: (2017)

Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
por: Evans, B. D., et al.
Publicado: (1984)

Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam
por: Tuan, Le Anh, et al.
Publicado: (2021)

New dosing schedules of dasatinib for CML and adverse event management
por: Wong, Siu-Fun
Publicado: (2009)

Dosing Schedules for Pneumococcal Conjugate Vaccine: Considerations for Policy Makers
por: Whitney, Cynthia G., et al.
Publicado: (2014)

Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
por: Gatault, Philippe, et al.
Publicado: (2015)

The Impact of Radiation on the Tumor Microenvironment: Effect of Dose and Fractionation Schedules
por: Arnold, Kimberly M, et al.
Publicado: (2018)

Near-infrared photoimmunotherapy: a comparison of light dosing schedules
por: Ogata, Fusa, et al.
Publicado: (2017)

Chronotherapy of Early Colon Cancer: Advantage of Morning Dose Schedules
por: Axelrod, David E
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2s2iv8a3ktidh6hu836vbrqh44